First Tracks Biotherapeutics posted "impressive" results for its celiac disease treatment Monday, and the IPO stock surged by double digits. The post Why This IPO Stock, An AnaptysBio Spinoff, Just Skyrocketed More Than 25% appeared first on Investor's Business Daily .
POLARIS INSIGHTS